Skip to main content
Caplight Logo









Emoface

Emoface

Private
GrenobleHealthcare & Life Scienceshttps://emoface.fr

Last Round

Grant

Dec 21, 2023

Total Funding Raised

$176,000

Company Overview

Emoface operates in Healthcare & Life Sciences and is based in Grenoble. Its latest recorded funding round was a Grant round in December 2023.

Emoface is an EdTech and MedTech company that develops digital therapy solutions using 3D avatars to support individuals with autism spectrum disorders and socio-emotional difficulties.

Sector

Healthcare & Life Sciences

Verticals

Mental Health, Patient Engagement, Vertical SaaS, Medical AI

Business Model

B2B

Customer Profile

Subscription SaaS

AI Layer

Application

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

Emoface Comparables

Compare Emoface with similar companies based on industry and business-model similarity.

Emoface comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Auticiel
81%
Otsimo
81%
Brighten Learning, Inc.
79%
Book a demo to see all comparables

For institutional investors. Book with your work email.

Emoface Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantDec 21, 2023
GrantJun 28, 2023
SeedMar 30, 2023
GrantNov 1, 2020
GrantJul 16, 2020
Book a demo to see all funding rounds

For institutional investors. Book with your work email.

Emoface Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 1, 2025

    Monthly visitors grew 361% MoM, reaching 1.6K.

  • Oct 29, 2024

    Monthly visitors increased 45% MoM, from 520 to 756.

Book a demo to see all signals

For institutional investors. Book with your work email.

Emoface Filings

Explore SEC and related filing metadata, where available.

Emoface filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about Emoface's valuation, stock price, and market status.

Is Emoface a public or private company?

Emoface is a private company.

What is the current stock price of Emoface?

Emoface is a private company, so its shares have no public market price. Caplight tracks Emoface's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is Emoface worth (valuation)?

Valuation information for Emoface is not publicly available.

Can I buy Emoface stock?

Emoface shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was Emoface's last funding round?

Emoface's most recent funding round was Grant on December 21, 2023.

Who are the main investors in Emoface?

Key investors in Emoface include European Innovation Council Fund, Région Auvergne-Rhône-Alpes, Bpifrance.

Will Emoface IPO soon?

No public IPO plans have been announced for Emoface.

How can I track Emoface secondary market activity?

Caplight tracks bids, offers, and trades in Emoface's shares on secondary markets.

Firmographic Details

HeadquartersGrenoble
Employee Range2
Year Founded2020
Last FundingDec 21, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?